Advertisement

Ken Berman

Ken Berman has been buying and selling stocks since he was a teenager and met with early success trading then-fledgling biotech stocks like Amgen, Biogen and Immunex. He later became a broker and worked for two wire houses, where he developed a proprietary system for buying and selling equities. In 1999, Mr. Berman formalized his method under the Gorilla Trades name and now has subscribers in the U.S. and 55 other countries around the world.

Latest Features

SLIDE SHOWApril 2020

In the midst of an economic scare as severe as this one, investors should look to blue-chip stocks to weather the storm. Many of these companies have massive financial resources that will allow them to ...

SLIDE SHOWMarch 2020

Health care, which makes up nearly 18% of American GDP, has long been a fruitful hunting ground for investors seeking growth. And medical-tech and medical-device stocks have always been particularly compelling ...

SLIDE SHOWOctober 2019

Stock buybacks are big business. In the second quarter of 2019 alone, S&P 500 companies spent almost $165 billion on share repurchases – and that was 26% less than the record high spent in Q4 2018.
But ...

SLIDE SHOWMay 2019

Gold prices have endured an up-and-down 2019 that has seen the yellow metal surge for the first couple months before sliding to a slight year-to-date loss. Still, gold stocks – the mining companies that ...

SLIDE SHOWApril 2019

Certain sectors of the stock market have gained a reputation for being income-friendly. If you want dividends, you know to look at utilities, consumer staples and real estate investment trusts (REITs). ...

SLIDE SHOWFebruary 2019

Pharmaceuticals are a tricky business. Public policy, science, R&D, global growth and regulation all play a role, sometimes outsize, in the success of pharmaceutical stocks.
But some Big Pharma companies ...

SLIDE SHOWDecember 2018

Genome sequencing – basically figuring out the order of DNA, the building blocks of life – was once essentially little more than a lab exercise. But now, it has reached commercial viability and then ...

SLIDE SHOWNovember 2018

The Standard & Poor’s 500-stock index is on pace for well-below-average gains in 2018. While the 2% improvement year-to-date isn’t exactly catastrophic, it is disappointing compared to most expectations ...

SLIDE SHOWOctober 2018

Many of us are unhappy with our health insurers. Premiums are high. Hospital bills can be large and deductibles for many policyholders are larger than ever.
But the world looks good if you own health ...

SLIDE SHOWSeptember 2018

Fintech cuts a wide swath, covering the digital, online and network-based tools and services used by banks, brokerages and other financial institutions. But while it is, by its very nature, technology, ...

SLIDE SHOWJuly 2018

Trade war tensions between the U.S. and China have only intensified over the past few months, causing a growing headache for investors. One day the market gains on optimism of a cease-fire between President ...

SLIDE SHOWJune 2018

Income investors can do well enough by staying domestic in their hunt for dividends. But they can add some oomph by branching out into international dividend stocks, which provide several benefits.
First, ...